Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült Államok2. fázis

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

A legfontosabb adatok

Hol
Ames, Anaconda, Ankeny, Ashland, Bellevue, Bethesda, Billings, Boone, Bozeman, Brainerd, Buffalo, Burlington, Canton, Carroll, Cedar Rapids, Charlottesville, Chicago, Cincinnati, City of Saint Peters, Cleveland, Clive, Coeur d'Alene, Columbus, Creve Coeur, Crown Point, Danville, Deer River, DeKalb, Derby, Des Moines, Duluth, Durham, Dyer, Effingham, Escanaba, Fargo, Fort Dodge, Geneva, Glenview, Grayslake, Great Falls, Green Bay, Guilford, Hibbing, Hobart, Hood River, Indianapolis, Janesville, Jefferson, Kalispell, La Crosse, Lake Forest, Los Angeles, Madison, Manistique, Marshalltown, Mattoon, Menomonee Falls, Milwaukee, Missoula, Mukwonago, Munster, New Berlin, New Haven, New Orleans, Newberg, Normal, Oak Brook, Oak Creek, Oconomowoc, Oconto Falls, Oklahoma City, Omaha, Oregon City, Orland Park, Philadelphia, Portland, Post Falls, Richmond, Sandpoint, Sandstone, Seattle, Sheboygan, Shiloh, Spooner, St Louis, Sturgeon Bay, Superior, Tucson, Urbana, Valparaiso, Virginia, Warrenville, Waukee, Waukesha, West Bend és West Chester (Egyesült Államok)Mind a 115 helyszín megnézése
Fázis
2. fázis

AI-kivonat: kiket keres a vizsgálat

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat olyan felnőtteket keres, akiknek az agresszív B-sejtes lymphomája (DLBCL vagy magas malignitású B-sejtes lymphoma) visszatért, vagy nem reagált a korábbi kezelésre. A ViPOR nevű kombinációt vizsgálják.

Életkor
18 éves vagy idősebb
Nem
Bármely nem részt vehet
A betegség stádiuma
Agresszív B-sejtes lymphoma, amely visszatért és/vagy nem reagált a kezelésre. 1. csoport: CD10-negatív DLBCL vagy hasonló típusok. 2. csoport: magas malignitású B-sejtes lymphoma MYC és BCL2 átrendeződéssel. A betegségnek mérhetőnek kell lennie.
Korábbi kezelés
Legalább 1 korábbi kezelés antraciklinnel és anti-CD20 antitesttel. Legfeljebb 3 korábbi kemoterápiás vonal. A regisztráció előtti 2 héten belül nem kaphatott kemoterápiát vagy célzott kezelést. A venetoclax, ibrutinib vagy lenalidomid (vagy hasonló szerek) közül legfeljebb egyet kaphatott korábban.
Biomarker vagy leletérték
1. csoport: CD10-negatív lymphoma. 2. csoport: MYC és BCL2 átrendeződés, BCL6 átrendeződéssel vagy anélkül. A laborvizsgálathoz elegendő daganatszövet szükséges.

A részvétel fő kizáró okai

  • Primer mediastinalis nagy B-sejtes lymphoma (igazolt vagy feltételezett)
  • Az idegrendszer elsődleges lymphomája
  • Terhesség
  • Aktív fertőzés a regisztrációkor
  • Átültetés vagy CAR-T kezelés a regisztráció előtti 3 hónapon belül

Gépi kiolvasás: 2026. november 10.

Helyszínek itt: Egyesült Államok

  • Mary Greeley Medical CenterAmes, Egyesült ÁllamokContact: Joseph J. Merchant (principal investigator)Résztvevőt keres
  • McFarland Clinic - AmesAmes, Egyesült ÁllamokContact: Joseph J. Merchant (principal investigator)Résztvevőt keres
  • Community Hospital of AnacondaAnaconda, Egyesült ÁllamokNo longer taking part
  • UI Health Care Mission Cancer and Blood - Ankeny ClinicAnkeny, Egyesült ÁllamokContact: Seema Harichand-Herdt (principal investigator)Résztvevőt keres
  • Duluth Clinic AshlandAshland, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Nebraska Medicine-BellevueBellevue, Egyesült ÁllamokContact: Snegha Ananth (principal investigator)Résztvevőt keres
  • National Institutes of Health Clinical CenterBethesda, Egyesült ÁllamokContact: Christopher J. Melani (principal investigator)Résztvevőt keres
  • Walter Reed National Military Medical CenterBethesda, Egyesült ÁllamokContact: Christin Destefano (principal investigator)Résztvevőt keres
  • Billings Clinic Cancer CenterBillings, Egyesült ÁllamokContact: John M. Schallenkamp (principal investigator)Résztvevőt keres
  • McFarland Clinic - BooneBoone, Egyesült ÁllamokNo longer taking part
  • Bozeman Health Deaconess HospitalBozeman, Egyesült ÁllamokNo longer taking part
  • Essentia Health Saint Joseph's Medical CenterBrainerd, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Roswell Park Cancer InstituteBuffalo, Egyesült ÁllamokContact: Alex Niu (principal investigator)Résztvevőt keres
  • University of Vermont and State Agricultural CollegeBurlington, Egyesült ÁllamokContact: James N. Gerson (principal investigator)Résztvevőt keres
  • University of Vermont Medical CenterBurlington, Egyesült ÁllamokContact: James N. Gerson (principal investigator)Résztvevőt keres
  • Aultman Health FoundationCanton, Egyesült ÁllamokContact: Aarthi Rajkumar (principal investigator)Résztvevőt keres
  • Saint Anthony Regional HospitalCarroll, Egyesült ÁllamokContact: Seema Harichand-Herdt (principal investigator)Résztvevőt keres
  • Mercy HospitalCedar Rapids, Egyesült ÁllamokContact: Deborah W. Wilbur (principal investigator)Résztvevőt keres
  • Oncology Associates at Mercy Medical CenterCedar Rapids, Egyesült ÁllamokContact: Deborah W. Wilbur (principal investigator)Résztvevőt keres
  • University of Virginia Cancer CenterCharlottesville, Egyesült ÁllamokContact: Craig A. Portell (principal investigator)Résztvevőt keres
  • Northwestern UniversityChicago, Egyesült ÁllamokContact: Reem Karmali (principal investigator)Résztvevőt keres
  • University of Cincinnati Cancer Center-UC Medical CenterCincinnati, Egyesült ÁllamokContact: Tahir Latif (principal investigator)Résztvevőt keres
  • Siteman Cancer Center at Saint Peters HospitalCity of Saint Peters, Egyesült ÁllamokContact: Brad S. Kahl (principal investigator)Résztvevőt keres
  • Case Western Reserve UniversityCleveland, Egyesült ÁllamokContact: Ali W. Bseiso (principal investigator)Résztvevőt keres
  • UI Health Care Mission Cancer and Blood - West Des Moines ClinicClive, Egyesült ÁllamokContact: Seema Harichand-Herdt (principal investigator)Résztvevőt keres
  • Kootenai Health - Coeur d'AleneCoeur d'Alene, Egyesült ÁllamokContact: John M. Schallenkamp (principal investigator)Résztvevőt keres
  • Ohio State University Comprehensive Cancer CenterColumbus, Egyesült ÁllamokContact: Kathryn Lurain (principal investigator)Résztvevőt keres
  • Siteman Cancer Center at West County HospitalCreve Coeur, Egyesült ÁllamokContact: Brad S. Kahl (principal investigator)Résztvevőt keres
  • Northwest Cancer Center - Crown PointCrown Point, Egyesült ÁllamokContact: Suparna Mantha (principal investigator)Résztvevőt keres
  • Carle at The RiverfrontDanville, Egyesült ÁllamokNo longer taking part
  • Essentia Health - Deer River ClinicDeer River, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Northwestern Medicine Cancer Center KishwaukeeDeKalb, Egyesült ÁllamokContact: Reem Karmali (principal investigator)Résztvevőt keres
  • Smilow Cancer Hospital-Derby Care CenterDerby, Egyesült ÁllamokContact: Shalin Kothari (principal investigator)Résztvevőt keres
  • Broadlawns Medical CenterDes Moines, Egyesült ÁllamokContact: Seema Harichand-Herdt (principal investigator)Résztvevőt keres
  • Iowa Methodist Medical CenterDes Moines, Egyesült ÁllamokContact: Seema Harichand-Herdt (principal investigator)Résztvevőt keres
  • UI Health Care Mission Cancer and Blood - Des Moines ClinicDes Moines, Egyesült ÁllamokContact: Seema Harichand-Herdt (principal investigator)Résztvevőt keres
  • UI Health Care Mission Cancer and Blood - Laurel ClinicDes Moines, Egyesült ÁllamokContact: Seema Harichand-Herdt (principal investigator)Résztvevőt keres
  • Essentia Health Cancer CenterDuluth, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Duke University Medical CenterDurham, Egyesült ÁllamokNo longer taking part
  • Northwest Oncology LLCDyer, Egyesült ÁllamokContact: Suparna Mantha (principal investigator)Résztvevőt keres
  • Carle Physician Group-EffinghamEffingham, Egyesült ÁllamokNo longer taking part
  • OSF Saint Francis Hospital and Medical GroupEscanaba, Egyesült ÁllamokContact: Brian L. Burnette (principal investigator)Résztvevőt keres
  • Essentia Health Cancer Center-South University ClinicFargo, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • McFarland Clinic - Trinity Cancer CenterFort Dodge, Egyesült ÁllamokContact: Joseph J. Merchant (principal investigator)Résztvevőt keres
  • UI Healthcare Mission Cancer and Blood - Fort DodgeFort Dodge, Egyesült ÁllamokContact: Seema Harichand-Herdt (principal investigator)Résztvevőt keres
  • Northwestern Medicine Cancer Center DelnorGeneva, Egyesült ÁllamokContact: Reem Karmali (principal investigator)Résztvevőt keres
  • Northwestern Medicine Glenview Outpatient CenterGlenview, Egyesült ÁllamokContact: Reem Karmali (principal investigator)Résztvevőt keres
  • Northwestern Medicine Grayslake Outpatient CenterGrayslake, Egyesült ÁllamokContact: Reem Karmali (principal investigator)Résztvevőt keres
  • Benefis Sletten Cancer InstituteGreat Falls, Egyesült ÁllamokContact: John M. Schallenkamp (principal investigator)Résztvevőt keres
  • Saint Vincent Hospital Cancer Center at Saint Mary'sGreen Bay, Egyesült ÁllamokContact: Brian L. Burnette (principal investigator)Résztvevőt keres
  • Saint Vincent Hospital Cancer Center Green BayGreen Bay, Egyesült ÁllamokContact: Brian L. Burnette (principal investigator)Résztvevőt keres
  • Smilow Cancer Hospital Care Center - GuilfordGuilford, Egyesült ÁllamokContact: Shalin Kothari (principal investigator)Résztvevőt keres
  • Essentia Health Hibbing ClinicHibbing, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Saint Mary Medical CenterHobart, Egyesült ÁllamokContact: Suparna Mantha (principal investigator)Résztvevőt keres
  • Providence Hood River Memorial HospitalHood River, Egyesült ÁllamokContact: Alison K. Conlin (principal investigator)Résztvevőt keres
  • Saint Catherine HospitalIndianapolis, Egyesült ÁllamokContact: Suparna Mantha (principal investigator)Résztvevőt keres
  • Mercyhealth Hospital and Cancer Center - JanesvilleJanesville, Egyesült ÁllamokContact: Emily G. Robinson (principal investigator)Résztvevőt keres
  • McFarland Clinic - JeffersonJefferson, Egyesült ÁllamokNo longer taking part
  • Logan Health Medical CenterKalispell, Egyesült ÁllamokNo longer taking part
  • Gundersen Lutheran Medical CenterLa Crosse, Egyesült ÁllamokContact: Kurt Oettel (principal investigator)Résztvevőt keres
  • Northwestern Medicine Lake Forest HospitalLake Forest, Egyesült ÁllamokContact: Reem Karmali (principal investigator)Résztvevőt keres
  • Cedars-Sinai Medical CenterLos Angeles, Egyesült ÁllamokContact: Justin M. Darrah (principal investigator)Résztvevőt keres
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical CenterMadison, Egyesült ÁllamokContact: Priyanka Pophali (principal investigator)Résztvevőt keres
  • University of Wisconsin Carbone Cancer Center - University HospitalMadison, Egyesült ÁllamokContact: Priyanka Pophali (principal investigator)Résztvevőt keres
  • Schoolcraft Memorial HospitalManistique, Egyesült ÁllamokContact: Brian L. Burnette (principal investigator)Résztvevőt keres
  • McFarland Clinic - MarshalltownMarshalltown, Egyesült ÁllamokContact: Joseph J. Merchant (principal investigator)Résztvevőt keres
  • Carle Physician Group-Mattoon/CharlestonMattoon, Egyesült ÁllamokNo longer taking part
  • Froedtert Menomonee Falls HospitalMenomonee Falls, Egyesült ÁllamokContact: Kaitlin Annunzio (principal investigator)Résztvevőt keres
  • Medical College of WisconsinMilwaukee, Egyesült ÁllamokContact: Kaitlin Annunzio (principal investigator)Résztvevőt keres
  • Community Medical CenterMissoula, Egyesült ÁllamokContact: John M. Schallenkamp (principal investigator)Résztvevőt keres
  • ProHealth D N Greenwald CenterMukwonago, Egyesült ÁllamokContact: Timothy R. Wassenaar (principal investigator)Résztvevőt keres
  • The Community HospitalMunster, Egyesült ÁllamokContact: Suparna Mantha (principal investigator)Résztvevőt keres
  • Women's Diagnostic Center - MunsterMunster, Egyesült ÁllamokContact: Suparna Mantha (principal investigator)Résztvevőt keres
  • Froedtert and MCW Moorland Reserve Health CenterNew Berlin, Egyesült ÁllamokContact: Kaitlin Annunzio (principal investigator)Résztvevőt keres
  • Yale UniversityNew Haven, Egyesült ÁllamokContact: Shalin Kothari (principal investigator)Résztvevőt keres
  • Ochsner Medical Center JeffersonNew Orleans, Egyesült ÁllamokNo longer taking part
  • Providence Newberg Medical CenterNewberg, Egyesült ÁllamokContact: Alison K. Conlin (principal investigator)Résztvevőt keres
  • Carle BroMenn Medical CenterNormal, Egyesült ÁllamokNo longer taking part
  • Carle Cancer Institute NormalNormal, Egyesült ÁllamokNo longer taking part
  • Northwestern Medicine Oak BrookOak Brook, Egyesült ÁllamokContact: Reem Karmali (principal investigator)Résztvevőt keres
  • Drexel Town Square Health CenterOak Creek, Egyesült ÁllamokContact: Kaitlin Annunzio (principal investigator)Résztvevőt keres
  • ProHealth Oconomowoc Memorial HospitalOconomowoc, Egyesült ÁllamokContact: Timothy R. Wassenaar (principal investigator)Résztvevőt keres
  • Saint Vincent Hospital Cancer Center at Oconto FallsOconto Falls, Egyesült ÁllamokContact: Brian L. Burnette (principal investigator)Résztvevőt keres
  • University of Oklahoma Health Sciences CenterOklahoma City, Egyesült ÁllamokNo longer taking part
  • Nebraska Medicine-Village PointeOmaha, Egyesült ÁllamokContact: Snegha Ananth (principal investigator)Résztvevőt keres
  • University of Nebraska Medical CenterOmaha, Egyesült ÁllamokContact: Snegha Ananth (principal investigator)Résztvevőt keres
  • Providence Willamette Falls Medical CenterOregon City, Egyesült ÁllamokContact: Alison K. Conlin (principal investigator)Résztvevőt keres
  • Northwestern Medicine Orland ParkOrland Park, Egyesült ÁllamokContact: Reem Karmali (principal investigator)Résztvevőt keres
  • Thomas Jefferson University HospitalPhiladelphia, Egyesült ÁllamokContact: Ubaldo E. Martinez Outschoorn (principal investigator)Résztvevőt keres
  • Providence Portland Medical CenterPortland, Egyesült ÁllamokContact: Alison K. Conlin (principal investigator)Résztvevőt keres
  • Providence Saint Vincent Medical CenterPortland, Egyesült ÁllamokContact: Alison K. Conlin (principal investigator)Résztvevőt keres
  • Kootenai Clinic Cancer Services - Post FallsPost Falls, Egyesült ÁllamokContact: John M. Schallenkamp (principal investigator)Résztvevőt keres
  • VCU Massey Comprehensive Cancer CenterRichmond, Egyesült ÁllamokContact: Bruce O. Hough (principal investigator)Résztvevőt keres
  • Kootenai Clinic Cancer Services - SandpointSandpoint, Egyesült ÁllamokContact: John M. Schallenkamp (principal investigator)Résztvevőt keres
  • Essentia Health SandstoneSandstone, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Swedish Medical Center-First HillSeattle, Egyesült ÁllamokContact: Alison K. Conlin (principal investigator)Résztvevőt keres
  • Saint Vincent Hospital Cancer Center at SheboyganSheboygan, Egyesült ÁllamokContact: Brian L. Burnette (principal investigator)Résztvevőt keres
  • Sheboygan Physicians GroupSheboygan, Egyesült ÁllamokContact: Brian L. Burnette (principal investigator)Résztvevőt keres
  • Memorial Hospital EastShiloh, Egyesült ÁllamokContact: Brad S. Kahl (principal investigator)Résztvevőt keres
  • Essentia Health-Spooner ClinicSpooner, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Siteman Cancer Center at Christian HospitalSt Louis, Egyesült ÁllamokContact: Brad S. Kahl (principal investigator)Résztvevőt keres
  • Siteman Cancer Center-South CountySt Louis, Egyesült ÁllamokContact: Brad S. Kahl (principal investigator)Résztvevőt keres
  • Washington University School of MedicineSt Louis, Egyesült ÁllamokContact: Brad S. Kahl (principal investigator)Résztvevőt keres
  • Saint Vincent Hospital Cancer Center at Sturgeon BaySturgeon Bay, Egyesült ÁllamokContact: Brian L. Burnette (principal investigator)Résztvevőt keres
  • Essentia Health Saint Mary's Hospital - SuperiorSuperior, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Banner University Medical Center - TucsonTucson, Egyesült ÁllamokNo longer taking part
  • University of Arizona Cancer Center-North CampusTucson, Egyesült ÁllamokNo longer taking part
  • Carle Cancer CenterUrbana, Egyesült ÁllamokNo longer taking part
  • Northwest Cancer Center - ValparaisoValparaiso, Egyesült ÁllamokContact: Suparna Mantha (principal investigator)Résztvevőt keres
  • Essentia Health Virginia ClinicVirginia, Egyesült ÁllamokContact: Bret E. Friday (principal investigator)Résztvevőt keres
  • Northwestern Medicine Cancer Center WarrenvilleWarrenville, Egyesült ÁllamokContact: Reem Karmali (principal investigator)Résztvevőt keres
  • UI Health Care Mission Cancer and Blood - Waukee ClinicWaukee, Egyesült ÁllamokContact: Seema Harichand-Herdt (principal investigator)Résztvevőt keres
  • UW Cancer Center at ProHealth CareWaukesha, Egyesült ÁllamokContact: Timothy R. Wassenaar (principal investigator)Résztvevőt keres
  • Froedtert West Bend Hospital/Kraemer Cancer CenterWest Bend, Egyesült ÁllamokContact: Kaitlin Annunzio (principal investigator)Résztvevőt keres
  • University of Cincinnati Cancer Center-West ChesterWest Chester, Egyesült ÁllamokContact: Tahir Latif (principal investigator)Résztvevőt keres

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

A vizsgálat adatai

Ki végzi
National Cancer Institute (NCI)
Azonosító
NCT06649812
A regiszteradat frissítve
2026. november 9.
Eredeti leírás
This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearrangements that has come back after a period of improvement (relapsed) and/or that has not responded to previous treatment (refractory). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Ibrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers at abnormal levels. This may help keep cancer cells from growing and spreading. Anti-inflammatory drugs, such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Obinutuzumab, a monoclonal antibody, binds to a protein called CD20, which is found on B cells and some types of leukemia and lymphoma cells. Obinutuzumab may block CD20 and help the immune system kill cancer cells. Revlimid, a type of anti-angiogenesis agent and a type of immunomodulating agent, may help the immune system kill abnormal blood cells or cancer cells. It may also prevent the growth of new blood vessels that cancers need to grow. ViPOR may be an effective treatment option for patients with relapsed and/or refractory CD10 negative DLBCL and high-grade B-cell lymphoma with MYC and BCL2 rearrangements.A teljes eredeti leírásKevesebb

A Phase II Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or Refractory CD10-Negative Diffuse Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements (HGBCL-DH-BCL2)

This phase II trial tests how well venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid® (ViPOR) works in treating patients with CD10 negative diffuse large B-cell lymphoma (DLBCL) and high-grade lymphoma with MYC and BCL2 rearrangements that has come back after a period of improvement (relapsed) and/or that has not responded to previous treatment (refractory). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Ibrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers at abnormal levels. This may help keep cancer cells from growing and spreading. Anti-inflammatory drugs, such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Obinutuzumab, a monoclonal antibody, binds to a protein called CD20, which is found on B cells and some types of leukemia and lymphoma cells. Obinutuzumab may block CD20 and help the immune system kill cancer cells. Revlimid, a type of anti-angiogenesis agent and a type of immunomodulating agent, may help the immune system kill abnormal blood cells or cancer cells. It may also prevent the growth of new blood vessels that cancers need to grow. ViPOR may be an effective treatment option for patients with relapsed and/or refractory CD10 negative DLBCL and high-grade B-cell lymphoma with MYC and BCL2 rearrangements.

Bevonási feltételek: Patient must be ≥ 18 years of age; Patient must have histologically or cytologically confirmed aggressive B-cell lymphoma as follows:; Cohort 1: CD10-negative DLBCL, which includes:; CD10-negative non-GCB DLBCL, not otherwise specified (NOS) (i.e., CD10-/BCL6- or CD10-/BCL6+/MUM1+ DLBCL); CD10-negative GCB DLBCL, NOS (i.e., CD10-/BCL6+/MUM1- DLBCL); CD10-negative HGBCL with MYC and BCL6 (without BCL2) translocations (HGBCL-DH-BCL6); CD10-negative HGBCL, NOS (without MYC and BCL2 translocations); CD10-negative T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) OR; Cohort 2: CD10-positive or negative HGBCL with MYC and BCL2 rearrangements (with or without BCL6 rearrangement) (HGBCL-DH-BCL2); NOTE: The site principal investigator must review and verify the pathology report findings to ensure the patient is eligible and is assigned to the respective cohort at the time of registration; Patient must have relapsed and/or refractory disease after at least 1 prior anthracycline and anti-CD20 antibody-containing regimen; Patient must not have confirmed or suspected primary mediastinal large B-cell lymphoma (PMBL); Patient must not be pregnant due to the potential harm to an unborn fetus with the treatment regimens being used; All patients of childbearing potential must have a serum or urine study with a sensitivity of at least 25 mIU/mL within 14 days prior to registration to rule out pregnancy and again within 24 hours prior to starting cycle 1 day 1 of treatment; A patient of childbearing potential is defined as anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months); Patients of childbearing potential must not expect to conceive children by abstaining from sexual intercourse or by using accepted and effective methods of contraception throughout the entire duration of protocol treatment, including during dose interruptions, and for 6 months after the last dose of protocol treatment. Male patients must not father children by abstaining from sexual intercourse or by using a condom during sexual contact with pregnant partners or partners of childbearing potential throughout the entire duration of protocol treatment, including dose interruptions, and for 6 months after the last dose of protocol treatment even if they have had a successful vasectomy; Male patients must agree to not donate semen or sperm during the entire duration of protocol treatment or for at least 28 days after the last dose of lenalidomide; Patient must agree to abstain from breastfeeding during the entire duration of protocol treatment and for at least 6 months after the last dose of protocol treatment; Patient must agree to abstain from donating blood during the entire duration of protocol treatment and for at least 28 days after the last dose of lenalidomide; Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible; Absolute neutrophil count (ANC) ≥ 1,000/mcL without requirement for granulocyte colony stimulating factor (G-CSF) support (obtained ≤ 7 days prior to registration); Hemoglobin ≥ 8 g/dL (obtained ≤ 7 days prior to registration); Platelets ≥ 75,000/mcL without requirement for platelet transfusion support (obtained ≤ 7 days prior to registration); Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (or ≤ 3.0 x institutional ULN for patients with documented Gilberts syndrome) (obtained ≤ 7 days prior to registration); Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) ≤ 3.0 x institutional ULN (obtained ≤ 7 days prior to registration); Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 30 mL/min/1.73 m\^2 (estimated by Cockcroft-Gault method or measured) (obtained ≤ 7 days prior to registration); Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial; For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated; Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load; Patient must not have confirmed or suspected primary DLBCL of the central nervous system (CNS) (PCNSL); Patients with history of secondary CNS lymphoma (SCNSL) are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression; Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial; Patient must not have taken or require warfarin or other strong CYP3A inhibitors or inducers within 7 days prior to registration; NOTE: Antiplatelet agents, other anticoagulants aside from warfarin, as well as mild or moderate CYP3A inhibitors or inducers are permitted on study but should be used with caution; Patient must not have an uncontrolled intercurrent illness that would interfere with the safety or efficacy assessment of this protocol; Patient must not have evidence of an active infection at the time of registration; Patient must not have the following current or prior anti-cancer treatment:; Any chemotherapy, targeted therapy, anti-cancer antibodies, antibody-drug conjugates, or bi-specific antibodies received within 2 weeks prior to registration; NOTE: Short courses of corticosteroids or palliative external beam radiation therapy (XRT) prior to registration are permitted; More than 3 prior lines of cytotoxic chemotherapy, excluding targeted therapy, anti-cancer antibodies, antibody-drug conjugates, bi-specific antibodies, and radio- or toxin-immunoconjugates; NOTE: Cytoreductive chemotherapy followed by autologous stem cell transplant (ASCT) counts as 1 line of cytotoxic therapy. Similarly, cytoreductive chemotherapy (either pre-T-cell collection or as bridging therapy) followed by pre-conditioning therapy/chimeric antigen receptor T-cell (CAR-T) counts as 1 line of therapy, as long as no disease progression occurs between interventions. For both therapies, if progressive disease is documented between 2 distinct regimens, then they should be counted as 2 lines of cytotoxic chemotherapy; Radio- or toxin-immunoconjugates within 10 weeks prior to registration; Previous treatment with more than one of the following study agents: venetoclax (or another BCL2 inhibitor), ibrutinib (or another BTK inhibitor), or lenalidomide (or another immunomodulatory imide drug [IMiD]); Prior autologous stem cell transplant (ASCT), chimeric antigen receptor T-cell (CAR-T) therapy, or allogeneic stem cell (or other organ) transplant within 3 months prior to registration; Any evidence of active graft-versus-host disease or requirement for immunosuppressants within 28 days prior to registration; NOTE: In addition, patient must have recovered (i.e., ≤ grade 1 or baseline) from all adverse events due to previously administered anti-cancer treatment, surgery, or procedure; NOTE: Exceptions to this include events not considered to place the patient at unacceptable risk of participation in the opinion of the treating investigator (i.e., alopecia); Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better; Patient must have adequate formalin fixed paraffin embedded (FFPE) tumor tissue specimen from the initial diagnostic biopsy or on-study repeat tumor tissue biopsy for molecular analysis; NOTE: Excisional tumor biopsy is preferred. Core needle biopsies will be considered adequate if there is enough tissue for the mandatory molecular analysis. Submission of an entire FFPE tumor block is preferred, but if unavailable 10 x 10um FFPE scrolls may be submitted as an alternative. If adequate archived FFPE tumor tissue is unavailable, the patient must be willing to undergo research biopsy for molecular analysis; Patient must have measurable disease; Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

ClinicalTrials.gov NCT06649812